Healthcare businesses tend to hold up through various economic cycles.

The healthcare sector is a beacon of resilience, consistently weathering economic storms while continuing to provide essential products and services. As we navigate the cyclical nature of the stock market, investing in healthcare stocks remains a wise strategy for long-term growth.

This July, two ASX-listed healthcare companies stand out as must-have additions to your portfolio: Imugene (ASX: IMU) and OncoSil Medical (ASX: OSL). Here’s why these stocks should be on your buy list.

1. Immugene (ASX: IMU)

Imugene focuses on cancer immunotherapy, developing a range of novel therapies that harness the body's immune system to fight cancer. The company’s innovative pipeline and strategic partnerships make it a compelling investment opportunity.

Early results are promising, and with the global cancer immunotherapy market expected to hit a whopping $172 billion by 2027, Immugene is positioned to be a major player.

Imugene's lead candidate, HER-Vaxx, targets HER-2 positive gastric cancer, and its pipeline includes promising therapies for other cancers such as PD1-Vaxx and CF33, which have the potential to revolutionise cancer treatment by enhancing the body's immune response to cancer cells. Recent clinical trial results for HER-Vaxx have shown encouraging efficacy and safety profiles, and as these trials progress, positive data could significantly boost Imugene's market position and stock price. Imugene has formed strategic alliances with leading research institutions and pharmaceutical companies, enhancing its research capabilities and accelerating the development of its innovative treatments. With the global market for cancer immunotherapies expected to grow exponentially, Imugene is well-positioned to capture a significant share of this lucrative market.

2. OncoSil Medical (ASX: OSL) 

OncoSil Medical is a notable company in the ASX healthcare sector, specialising in localised radiation therapy for pancreatic cancers. The company offers a crucial approach to treating these challenging diseases.

OncoSil Medical’s product, the OncoSil device, delivers targeted beta radiation directly into tumours using Phosphorous 32 microparticles. This method aims to minimise damage to surrounding healthy tissues, providing a significant treatment option for patients with pancreatic cancer, which has one of the lowest survival rates among all cancers. The OncoSil™ device has received CE marking in Europe and breakthrough device designation from the FDA, validating its efficacy and safety and paving the way for market expansion into the US and other regions. Clinical trials and real-world data support the effectiveness of the OncoSil™ device in targeting pancreatic tumours. As more positive data emerges, the adoption of this technology is expected to increase, driving revenue growth. With strategic funding and revenue from its European operations, OncoSil Medical has a solid financial base to invest in further research and development, positioning it for long-term growth.

Why are these two healthcare heroes perfect for your July portfolio?

• Innovation: Both Immugene and Oncosil are at the forefront of their respective fields, with potentially groundbreaking technologies.
• Growth Potential: The global cancer treatment market is massive and growing, offering these companies a huge potential customer base.
• Aussie Advantage: Let's face it, we love supporting our homegrown heroes! Plus, the ASX can sometimes offer exciting opportunities under the radar of the bigger markets.

As you consider where to invest in July, Imugene (ASX: IMU) and OncoSil Medical (ASX: OSL) stand out as top picks in the healthcare sector. Their innovative approaches to cancer treatment, strong clinical data, and strategic growth plans make them compelling investment opportunities. Adding these stocks to your portfolio could provide both financial growth and the satisfaction of supporting companies that are making a real difference in the fight against cancer. 

Ready to ride the healthcare wave? Don’t miss out on the potential gains from these groundbreaking companies. Make sure to add Imugene and OncoSil Medical to your buy basket this July!